Leap Therapeutics, Inc.
(NASDAQ : LPTX)

( )
LPTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.57%283.291.5%$876.09m
GILDGilead Sciences, Inc. -0.02%87.961.0%$686.29m
MRNAModerna, Inc. -1.36%173.540.0%$642.89m
REGNRegeneron Pharmaceuticals, Inc. -1.06%747.472.6%$489.87m
VRTXVertex Pharmaceuticals, Inc. -1.82%311.811.9%$475.10m
BIIBBiogen, Inc. -0.44%291.471.8%$409.07m
ILMNIllumina, Inc. -3.69%205.983.2%$225.66m
BMRNBioMarin Pharmaceutical, Inc. -1.27%102.224.2%$161.73m
BNTXBioNTech SE -3.05%161.620.0%$160.60m
AXSMAxsome Therapeutics, Inc. -2.63%75.261.6%$141.48m
SNSSSunesis Pharmaceuticals, Inc. -6.51%2.010.7%$140.51m
MRTXMirati Therapeutics, Inc. -22.89%71.521.6%$125.68m
HALOHalozyme Therapeutics, Inc. 0.79%56.3818.4%$81.14m
NVAXNovavax, Inc. -4.71%16.7875.3%$80.38m
IMGOImago BioSciences, Inc. 0.00%35.860.0%$59.53m

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.